
ImpediMed Investor Relations Material
Latest events

Q4 2025
ImpediMed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImpediMed Limited
Access all reports
ImpediMed Limited is an Australian medical technology company specializing in bioimpedance spectroscopy (BIS) technology for non-invasive health assessments. The company’s primary products focus on the early detection, monitoring, and management of lymphedema, as well as body composition and fluid status assessments. ImpediMed’s technology is used in healthcare settings to support patient care in oncology, renal health, and other medical fields where fluid management is critical. ImpediMed Limited is headquartered in Brisbane, Australia, and its shares are listed on the ASX.
Key slides for ImpediMed Limited


Q2 2025 TU
ImpediMed Limited


Q4 2025
ImpediMed Limited
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
IPD
Country
🇦🇺 Australia